Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2019

View Archived Issues

Mutation in MIR140 gene tied to skeletal dysplasia

Theranexus presents preliminary results of phase II study of THN-102 on patients with narcolepsy

Shionogi and Nagasaki University to collaborate in the field of infectious diseases

Hinova Pharmaceuticals describes new antitubercular compounds

Hiroshima University and collaborators present new PPIase Pin1 inhibitors

Technique boosts single-cell level grasp of DNA replication

ViiV Healthcare enters collaboration with Radboud University Medical Center

New STAT3 inhibitors discovered at King's College London

Amgen presents promising preclinical data for AMG-160

Teligene patents high affinity nerve growth factor receptor inhibitors

MDI-2268 shows safety and efficacy in murine model of deep vein thrombosis

Bromodomain-containing protein 4 inhibitors identified at Zhejiang Hisun Pharmaceutical

FDA allows initiation of phase I study of CT-044

AbCellera enters antibody discovery collaboration in neurology with Denali

Takeda Pharmaceutical presents the discovery of novel potent and selective Nav1.1 activator

Single-nulceotide polymorphism in ADGRL3 gene found predictor of substance use disorder

Azetidine optimization leads to clinical candidate JTE-952 for rheumatoid arthritis

Abpro and NJCTTQ partner to develop bispecific antibody therapies in immuno-oncology

Apellis enters collaboration with SFJ Pharmaceuticals for APL-2 in hematologic indications

Researchers find biomarkers associated with risk of GvHD

Minoryx receives Spanish clearance to begin phase II trial of MIN-102 in Friedreich's ataxia

Topivert Pharma initiates phase II/III study of TOP-1630 in dry eye syndrome

Armed oncolytic adenovirus targets tumor stroma to enhance viral spread

Phase III FORWARD I trial of mirvetuximab soravtansine does not meet primary endpoint

FDA approves Herceptin Hylecta for HER2-positive breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...